Eccrine sweat secretion is studied during physical stress after the administration of a B-blocking agent: Butofilolol. 20 voluntary normotensive subjects, age 24 + 2 ans are submitted to 2 exercises stress test (ergometric bicycle) performed at on week interval. Butofilolol is administrated at a posology of 200 mg, 24 hours and 2 hours, before the test as well as placebo (double blind). Local sweat output is measured 1 min after stress and in the interscapulary region with an evaporimeter. Sweat weight, sweat electrolyte concentrations (sodium, chloride) are analysed from filters papers placed on the forehead. With butofilolol, significative increases of sweet output (+13%), sweat weight (+20%), and sodium (+20%), chloride (+26%) elimination are observed. The subjective observation of the effects of B-blocking agents is confirmed. The way of action of Butofilolol discussed.

01 Jan 1984·International journal of clinical pharmacology research

Pharmacokinetics of butofilolol (CAFIDE) after repeated oral administration in man.

Article

Author: Houin, G ; Jeanniot, J P ; Tillement, J P ; Barre, J ; Cautreels, W ; Ledudal, P

The pharmacokinetics of butofilolol, a new beta-blocking drug, was studied in 6 healthy subjects. Plasma concentrations and urinary excretion of the unchanged drug were determined after a single 100-mg oral administration, and also during chronic treatment (100 mg/day for a week) and after the last dose. Maximum plasma concentrations were observed 2 to 3 h after drug administration and varied between the subjects (120 to 430 ng/ml). The apparent volumes of distribution were large, ranging between 200 I and 500 I, and the apparent clearances of elimination appeared to be intermediate between 40 and 70 l/h. Drug elimination in the urine (about 4% of administered dose) occurred by filtration, tubular secretion and pH-sensitive reabsorption following a non-linear process. However, pharmacokinetic parameters remained constant during chronic treatment, since urinary elimination of the parent drug was too low to influence its pharmacokinetic profile. In addition, a high correlation was found between plasma levels of butofilolol and the effect of the drug on resting heart rate, while a slight effect on diastolic blood pressure could be discerned.

01 Jan 1984·International journal of clinical pharmacology research

Butofilolol pharmacokinetics in chronic renal insufficiency.

Article

Author: Cautreels, W ; Jeanniot, J P ; Tillement, J P ; Houin, G ; Giudicelli, C P ; Ledudal, P

The pharmacokinetics of butofilolol, a new beta-blocking drug used in the treatment of hypertension, were investigated in 9 patients with varying degrees of renal impairment (creatinine clearance ranging from 65 ml/min to 6.6 ml/min). The drug was administered as a single oral 100-mg dose. Plasma and urine concentrations of the parent drug were measured. The pharmacokinetic parameters of butofilolol calculated from examination of patients with renal failure were compared to those obtained from healthy subjects. Renal failure was found to be associated with a marked increase of the areas under the plasma concentration-time curves of the parent drug whereas its elimination rate constant tended to increase, especially in severe renal failure. A highly significant relationship between the amounts of unchanged drug excreted in urine and the creatinine clearance was observed (r = 0.90, p less than 0.001). The higher plasma levels of the parent drug observed in renal failure might be due to a decrease in the first-pass hepatic extraction of the drug. But these changes in plasma clearance were probably counteracted by modification of the volume of distribution, so that the net result of these alterations was a slight increase in the elimination half-life.

100 Deals associated with Butofilolol

External Link

KEGG	Wiki	ATC	Drug Bank
-	Butofilolol	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension	Phase 1	-	Sanofi	01 Jun 1983

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis